1. Home
  2. HBB vs ADCT Comparison

HBB vs ADCT Comparison

Compare HBB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

HOLD

Current Price

$16.59

Market Cap

217.9M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.53

Market Cap

483.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
ADCT
Founded
1904
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.9M
483.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
HBB
ADCT
Price
$16.59
$3.53
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
30.8K
2.0M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
2.91%
N/A
EPS Growth
24.53
N/A
EPS
2.34
N/A
Revenue
$607,430,000.00
$75,209,000.00
Revenue This Year
N/A
$10.36
Revenue Next Year
N/A
$3.87
P/E Ratio
$7.06
N/A
Revenue Growth
N/A
6.35
52 Week Low
$12.72
$1.05
52 Week High
$21.20
$4.80

Technical Indicators

Market Signals
Indicator
HBB
ADCT
Relative Strength Index (RSI) 60.38 42.49
Support Level $15.62 $3.35
Resistance Level $17.23 $4.05
Average True Range (ATR) 0.73 0.27
MACD -0.03 -0.03
Stochastic Oscillator 80.90 22.77

Price Performance

Historical Comparison
HBB
ADCT

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: